Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Inspection Record
RC Compounding Services, LLC — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Routine calibration and checking of equipment is not performed according to a written program designed to assure proper performance.
Buildings used in the manufacture, processing, packing or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce a septic con ditions.
Clothing of personnel engaged in the manufacturing of drug products is not appropriate for the duties they perform.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Procedures des igned to prevent microbiological contamination of drug products purporting to be sterile do not include v alidation of the sterilization process .
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
About this record
Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
